SEC Form 4 · accession 0001079973-26-000801
Starling Oncology, Inc. · STLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yale Podnos
Officer — Chief Medical Officer
Period of report
Jun 8, 2026
Accepted (ET)
Jun 9, 2026 · 7:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001799191
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2026 | S | 23,451 | $5.3769 | D | 259,527 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Price is the volume weighted average selling price of all sales on behalf of the Reporting Person on June 8, 2028 within a one-dollar range. Actual prices ranged from $5.35 to $5.42. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.
- F2Sales were made on behalf of the Reporting Person pursuant to the Rule 10b5-1(c) plan that was adopted on 08/26/2025.